FDA Inspection 1050153 — Centrient Pharmaceuticals India Private Limited
The FDA completed an inspection of Centrient Pharmaceuticals India Private Limited on April 20, 2018 in Nawashahr. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- April 20, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Nawashahr (India)